Etanercept and uveitis: Friends or foes?

Current Medical Research and Opinion

Volumn 31, Issue 2, 2015, Pages 251-252

  Brito Zerón, Pilar ^a   Perez Alvarez, Roberto ^b   Ramos Casals, Manuel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DO MEIXOEIRO   (Spain)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Uveitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CARDIOVASCULAR RISK; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EUROPEAN MEDICINES AGENCY; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY BOWEL DISEASE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT INDICATION; TREATMENT RESPONSE; UVEITIS; AUTOIMMUNITY; DRUG EFFECTS; IMMUNOLOGY; POSTMARKETING SURVEILLANCE; SPONDYLITIS, ANKYLOSING;

ANTIRHEUMATIC AGENTS; AUTOIMMUNITY; HUMANS; IMMUNOGLOBULIN G; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84923356096     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.993024     Document Type: Editorial

References (14)

1. Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter 2013;164:e413-28
2. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64
3. Ramos-Casals M, Brito-Zeron P, Munoz S, et al; BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008;87:345-64
4. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52
5. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, et al; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188-93
6. Wendling D, Paccou J, Berthelot JM, et al; CRI. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
7. Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 2014: published online 8 October 2014, 10.1185/03007995.2014.969368
8. Berg IJ, Semb AG, van der Heijde D, et al. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a crosssectional study. Semin Arthritis Rheum 2014: published online 20 May 2014, 10.1016/j.semarthrit.2014.05.017
9. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87
10. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
11. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
12. Cobo-Ibanez T, del Carmen Ordonez M, Munoz-Fernandez S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47:731-2
13. Rudwaleit M, Rdevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
14. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121:785-96.e3